ZA200802822B - Raf inhibitor compounds and methods of use thereof - Google Patents
Raf inhibitor compounds and methods of use thereofInfo
- Publication number
- ZA200802822B ZA200802822B ZA200802822A ZA200802822A ZA200802822B ZA 200802822 B ZA200802822 B ZA 200802822B ZA 200802822 A ZA200802822 A ZA 200802822A ZA 200802822 A ZA200802822 A ZA 200802822A ZA 200802822 B ZA200802822 B ZA 200802822B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- inhibitor compounds
- raf inhibitor
- raf
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71363005P | 2005-09-01 | 2005-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200802822B true ZA200802822B (en) | 2009-10-28 |
Family
ID=37744290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200802822A ZA200802822B (en) | 2005-09-01 | 2008-03-31 | Raf inhibitor compounds and methods of use thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070049603A1 (xx) |
EP (1) | EP1934228A2 (xx) |
JP (1) | JP2009507024A (xx) |
KR (1) | KR20080052630A (xx) |
CN (1) | CN101305010A (xx) |
AU (1) | AU2006284751A1 (xx) |
BR (1) | BRPI0615781A2 (xx) |
CA (1) | CA2620864A1 (xx) |
IL (1) | IL189771A0 (xx) |
NO (1) | NO20081595L (xx) |
RU (1) | RU2008112313A (xx) |
WO (1) | WO2007027855A2 (xx) |
ZA (1) | ZA200802822B (xx) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1979325A1 (en) * | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
ZA200900896B (en) * | 2006-08-21 | 2010-06-30 | Genentech Inc | Aza-benzofuranyl compounds and methods of use |
ES2376771T3 (es) * | 2006-08-21 | 2012-03-16 | Genentech, Inc. | Compuestos aza-benzofuranilo y métodos de utilización |
AU2007286807B2 (en) * | 2006-08-21 | 2013-03-21 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
MX2009002046A (es) * | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos. |
US20090325957A1 (en) * | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
JP5153777B2 (ja) | 2006-10-02 | 2013-02-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼとしての化合物および組成物 |
US8138183B2 (en) * | 2007-07-09 | 2012-03-20 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
WO2009007748A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
BRPI0814503A2 (pt) * | 2007-07-09 | 2017-05-16 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica |
WO2009007749A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
GB0714384D0 (en) * | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
WO2009093008A1 (en) * | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | RAF阻害化合物として使用されるイミダゾ[4,5−b]ピリジン誘導体 |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
AU2009222143A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール[3,4−b]ピリジンRAF阻害剤 |
GB0811304D0 (en) * | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
BRPI0910175A2 (pt) | 2008-07-01 | 2017-03-21 | Genentech Inc | composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero |
EP2307364B1 (en) | 2008-07-01 | 2013-06-19 | Genentech, Inc. | Isoindolone derivatives as mek kinase inhibitors and methods of use |
EP2330908A4 (en) * | 2008-08-15 | 2011-11-23 | Univ Georgetown | FLUORESCENT CDK INHIBITORS FOR CANCER TREATMENT |
WO2010028192A1 (en) | 2008-09-03 | 2010-03-11 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
UY32351A (es) * | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
US20130018033A1 (en) | 2009-08-28 | 2013-01-17 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
JP2013503194A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Rafキナーゼを阻害するための1H−ピラゾロ[3,4−B]ピリジン化合物 |
CA2771893A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
CA2772074A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
CA2771895A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
JP2013503193A (ja) | 2009-08-28 | 2013-01-31 | ジェネンテック, インコーポレイテッド | Raf阻害剤化合物およびその使用方法 |
NZ600926A (en) * | 2010-01-04 | 2013-07-26 | Nippon Soda Co | Nitrogen-containing heterocyclic compound and agricultural/horticultural germicide |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
US8937088B2 (en) | 2011-01-06 | 2015-01-20 | Astar Biotech Llc | Ureas for the treatment and prevention of cancer |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
JP5760813B2 (ja) * | 2011-07-29 | 2015-08-12 | 三菱化学株式会社 | チエノチオフェン化合物の製造方法 |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
EP2793938A4 (en) * | 2011-12-22 | 2015-07-22 | Glaxosmithkline Llc | METHOD OF TREATING CANCER USING A MAGE-A3 IMMUNOTHERAPEUTIC PRODUCT COMPRISING A BRAF INHIBITOR AND / OR MEK INHIBITOR |
ES2588775T3 (es) | 2011-12-31 | 2016-11-04 | Beigene, Ltd. | Compuestos tricíclicos fusionados como inhibidores de cinasa raf |
ES2656972T3 (es) | 2012-02-23 | 2018-03-01 | Vanderbilt University | Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4 |
JP2014237624A (ja) * | 2012-10-23 | 2014-12-18 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
WO2014143666A1 (en) | 2013-03-15 | 2014-09-18 | Biomarin Pharmaceutical Inc. | Hdac inhibitors |
JP6380862B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物 |
CN103382187B (zh) * | 2013-08-06 | 2015-06-03 | 信实生物医药(上海)有限公司 | 一种3-氯-7(5)-溴苯并异恶唑的合成方法 |
WO2015027214A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
EP3326095B1 (en) * | 2015-07-17 | 2024-02-07 | Life Technologies Corporation | Tool for visualizing pcr results |
CN105541863B (zh) * | 2016-02-16 | 2017-09-05 | 安纳康科学股份有限公司 | 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途 |
WO2017144341A1 (de) | 2016-02-23 | 2017-08-31 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
WO2019081477A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
WO2019081485A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
JP2022507888A (ja) * | 2018-11-21 | 2022-01-18 | ケース ウェスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法 |
LT3999038T (lt) * | 2019-07-17 | 2024-03-25 | Cytokinetics, Inc. | Širdies sarkomerų inhibitoriaus geriamosios vaistinės formos |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904672A (en) * | 1987-01-30 | 1990-02-27 | Merck & Co., Inc. | Derivatives of 3-hydroxyazabenzo[b]thiophene useful as 5-lipoxygenase inhibitors |
US4767766A (en) * | 1987-01-30 | 1988-08-30 | Merck & Co., Inc. | Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors |
DE3710937A1 (de) * | 1987-04-01 | 1988-10-13 | Boehringer Mannheim Gmbh | Chromogene verbindungen, ihre herstellung und verwendung als enzymsubstrate |
US5811432A (en) * | 1990-11-09 | 1998-09-22 | Pfizer Inc | Azaoxindole derivatives |
US5252581A (en) * | 1992-07-20 | 1993-10-12 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted aminothienopyridines, pharmaceutical composition and use |
US5272148A (en) * | 1992-09-09 | 1993-12-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Heteroarenylpiperazines |
FR2732969B1 (fr) * | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9614718D0 (en) * | 1996-07-12 | 1996-09-04 | Bayer Ag | 3-ureido-pyridofurans and -pyridothiophenes |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
AR036040A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
EP1425286B1 (en) * | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
HUP0402289A2 (hu) * | 2001-10-02 | 2005-02-28 | Pharmacia & Upjohn Company | Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
US6849620B2 (en) * | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
JP2005104838A (ja) * | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
TW200418830A (en) * | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
US7250415B2 (en) * | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
TWI312345B (en) * | 2003-06-30 | 2009-07-21 | Mitsubishi Tanabe Pharma Corp | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives |
DE10351436A1 (de) * | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
US7145023B2 (en) * | 2003-11-20 | 2006-12-05 | Cognis Corporation | Processes for preparing solid tocopherol succinate calcium and magnesium salts |
SI1747220T1 (sl) * | 2003-12-11 | 2009-08-31 | Aventis Pharma Inc | Substituirani 1H-pirolo(3,2-b, 3,2-c in 2,3-c)piridin-2-karboksamidi in sorodni analogi kot inhibitorji kazein kinaze I epsilon |
US20070149553A1 (en) * | 2003-12-19 | 2007-06-28 | Arrington Kenneth L | Mitotic kinesin inhibitors |
TW200607503A (en) * | 2004-05-17 | 2006-03-01 | Tibotec Pharm Ltd | 1-heterocyclyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones |
US7875627B2 (en) * | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
-
2006
- 2006-08-31 US US11/513,625 patent/US20070049603A1/en not_active Abandoned
- 2006-08-31 CN CNA2006800410372A patent/CN101305010A/zh active Pending
- 2006-08-31 WO PCT/US2006/033976 patent/WO2007027855A2/en active Application Filing
- 2006-08-31 JP JP2008529260A patent/JP2009507024A/ja not_active Withdrawn
- 2006-08-31 CA CA002620864A patent/CA2620864A1/en not_active Abandoned
- 2006-08-31 EP EP06813989A patent/EP1934228A2/en not_active Withdrawn
- 2006-08-31 RU RU2008112313/04A patent/RU2008112313A/ru not_active Application Discontinuation
- 2006-08-31 KR KR1020087007829A patent/KR20080052630A/ko not_active Application Discontinuation
- 2006-08-31 AU AU2006284751A patent/AU2006284751A1/en not_active Abandoned
- 2006-08-31 BR BRPI0615781-5A patent/BRPI0615781A2/pt not_active Application Discontinuation
-
2008
- 2008-02-26 IL IL189771A patent/IL189771A0/en unknown
- 2008-03-31 ZA ZA200802822A patent/ZA200802822B/xx unknown
- 2008-03-31 NO NO20081595A patent/NO20081595L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2620864A1 (en) | 2007-03-08 |
CN101305010A (zh) | 2008-11-12 |
NO20081595L (no) | 2008-06-02 |
BRPI0615781A2 (pt) | 2009-06-16 |
WO2007027855A2 (en) | 2007-03-08 |
KR20080052630A (ko) | 2008-06-11 |
US20070049603A1 (en) | 2007-03-01 |
EP1934228A2 (en) | 2008-06-25 |
WO2007027855A3 (en) | 2007-05-03 |
JP2009507024A (ja) | 2009-02-19 |
RU2008112313A (ru) | 2009-10-10 |
IL189771A0 (en) | 2008-08-07 |
AU2006284751A1 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200802822B (en) | Raf inhibitor compounds and methods of use thereof | |
ZA200710969B (en) | Raf inhibitor compounds and methods of use thereof | |
ZA200707289B (en) | Raf inhibitor compounds and methods | |
IL176958A0 (en) | Compounds and methods of use | |
ZA200709751B (en) | Thiazole compounds and methods of use | |
IL186490A0 (en) | Multicyclic compounds and methods of their use | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
IL207843A0 (en) | Raf inhibitor compounds and methods of use thereof | |
EP2023718A4 (en) | CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR | |
IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
IL189602A0 (en) | Indenoisoquinolinone analogs and methods of use thereof | |
SG10201504801VA (en) | Azaindazole compounds and methods of use | |
EP1913112A4 (en) | SUPPORTING AGENT AND METHODS OF USE | |
IL185914A0 (en) | Pyrimidine compounds and methods of use | |
EP1931205A4 (en) | TRANSGLUTAMINASE INHIBITORS AND METHOD OF USE THEREOF | |
IL194028A0 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
HK1135099A1 (en) | Aza-indolyl compounds and methods of use | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
EP1812451A4 (en) | COMPOUNDS AND METHODS OF USE THEREOF | |
IL190226A0 (en) | Organometallic compounds and methods of use thereof | |
EP1789437A4 (en) | INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF | |
ZA200804681B (en) | Inhibitors of C-Met and uses thereof | |
EP1883404A4 (en) | P38 INHIBITORS AND METHODS OF USE |